Takeda’s lung cancer treatment Alunbrig proves successful in Phase III trial
pharmafile | September 26, 2018 | News story | Research and Development | Alunbrig, R&D, Takeda, phase III, research
Japanese pharma firm Takeda have announced that lung cancer treatment Alunbrig has proven successful in reducing the risk of disease progression or death by more than 50% in comparison with crizotinib in adult patients with anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor.
The findings were presented at the 19th World Conference on Lung Cancer in Toronto and published online in The New England Journal of Medicine.
The Phase III ALTA-L1 trial involving 275 patients demonstrated Alunbrig’s safety and efficacy in bringing about a 51% reduction in the risk of disease progression or death.
The ALK+ NSCLC treatment landscape has experienced tremendous change over the last decade, and the ALTA-1L trial demonstrates that brigatinib has the potential to be a key player in the first-line setting,” said D. Ross Camidge, lead investigator of ALTA-1L. “The ALTA-1L trial offers unique aspects, including the real-world applicability of the data. The study’s design offered enrollment to a broader population by allowing patients to participate even if they had received prior chemotherapy and enrolled patients based on local standard of care ALK testing as opposed to mandating confirmation at a central lab. We look forward to further follow-up, which will provide even better understanding of the role of brigatinib in the evolving landscape
“We are thrilled to share these highly anticipated results with the lung cancer community,” said Dr David Kerstein, Global Clinical Lead for Brigatinib and Lung Cancer Clinical Portfolio Strategy Lead, Takeda. “The ALTA-1L data demonstrate that ALUNBRIG is superior to crizotinib in the first-line setting, reducing disease progression or death by more than half, with particularly pronounced activity in the brain. We would like to thank all the investigators, and especially the patients and their caregivers who participated in this important clinical research.”
Louis Goss
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
